| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lutein (L; xanthophyll carotenoid) — dietary pigment concentrated in the macula (with zeaxanthin) forming macular pigment; sourced from leafy greens (kale/spinach), corn, egg yolk, and supplements (often paired with zeaxanthin). Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Fat-soluble; absorption improves with dietary fat; plasma lutein rises dose-dependently with supplementation and accumulates in retina (macular pigment). Long-term dosing (weeks–months) is typical for tissue effects. In-vitro vs oral exposure: Most direct anti-cancer cytotoxicity requires supra-physiologic concentrations (high concentration only); clinical relevance is strongest for eye outcomes (AMD risk progression). Clinical evidence status: Supported within AREDS2-style formulations for reducing progression risk in intermediate → advanced AMD (eye-specific benefit); cancer evidence remains preclinical. Lutein-Kale, spinach, parsley, corn, egg yolks, peas -Breast cancer: Inverse correlation with dietary intake - Potent antioxidant, scavenges ROS (reactive oxygen species) -Downregulates NF-κB and other inflammatory pathways -Promotes apoptosis in cancer cells -inhibits angiogenesis Lutein — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Lutein — AD relevance: Lutein preferentially accumulates in the brain and has been linked to neural efficiency and modest cognitive performance effects in older adults; mechanisms emphasize antioxidant/anti-inflammatory protection and membrane/synaptic support. Evidence is supportive but not disease-modifying. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Chronic intake increases circulating lutein and is associated with higher macular pigment (used as a biomarker linked to brain lutein status). Effects are generally time-dependent (months). Clinical evidence status: Small RCTs and imaging trials in older adults show signals for neural efficiency/cognition; AD-specific clinical evidence remains limited. Lutein — AD / Neurodegeneration Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| custom |
| 3984- | Lut, | VitE, | Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study |
| - | Study, | AD, | NA |
| 4195- | Lut, | Zeax, | Low Xanthophylls, Retinol, Lycopene, and Tocopherols in Grey and White Matter of Brains with Alzheimer’s Disease |
| - | Human, | AD, | NA |
| 3983- | Lut, | Zeax, | The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial |
| - | Trial, | AD, | NA |
| 3981- | Lut, | Zeax, | VitE, | Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial |
| - | Trial, | AD, | NA |
| 3979- | Lut, | Increases in Plasma Lutein through Supplementation Are Correlated with Increases in Physical Activity and Reductions in Sedentary Time in Older Adults |
| - | Trial, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:349 Target#:767 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid